West Pharmaceutical Services Reports Strong Q1 2026 Earnings with Revenue Growth and Guidance Update
West Pharmaceutical Services, Inc. reported a 15.3% organic revenue growth in Q1 2026, driven by strong demand for High-Value Product (HVP) components and biologics. The company raised its full-year organic revenue guidance to 7% to 9% and adjusted EPS guidance to $8.40 to $8.75, citing margin expansion and favorable product mix.
Tickers: $WST
Topics: Biosimilars Earnings Call GLP-1 Demand Guidance Update HVP Components Margin Expansion Organic Growth Revenue Growth